. Author manuscript; available in PMC: 2019 Aug 1.

Published in final edited form as: Nat Rev Drug Discov. 2019 Feb;18(2):139–158. doi: 10.1038/s41573-018-0003-2

Table 6 |.

Organ-specific therapies

Therapeutic agent	Properties	Comments
Varespladib	Inhibits secretary phospholipase A2	Studied in 30 patients at risk for acute chest syndrome (NCT00434473), results not published
Bosentan	Inhibits endothelin	Prevented hypoxia-induced mortality and morbidity in SCD mice;¹⁷⁵ Modest improvement in some SCD patients with pulmonary hypertension¹⁷⁶
ACE inhibitors (e.g. lisinopril, enalapril, captopril)	Angiotensin converting enzyme inhibition reduces albuminuria and slows progression of other nephropathies	Mixed results regarding ability to reduce albuminuria in SCD ^{180,181,280,281}
Losartan	Inhibits angiotensin receptor, expected to reduce albuminuria	A phase 2 trial showed efficacy in reducing albuminuria;¹⁸³ no phase 3 randomized clinical trials conducted